CN106727657A - A kind of Western medicine compound for treating diabetes and application - Google Patents
A kind of Western medicine compound for treating diabetes and application Download PDFInfo
- Publication number
- CN106727657A CN106727657A CN201611227528.8A CN201611227528A CN106727657A CN 106727657 A CN106727657 A CN 106727657A CN 201611227528 A CN201611227528 A CN 201611227528A CN 106727657 A CN106727657 A CN 106727657A
- Authority
- CN
- China
- Prior art keywords
- western medicine
- medicine compound
- parts
- group
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of Western medicine compound for treating diabetes and application, the active component of the Western medicine compound is made up of 1.2 1.7 parts of Korea's silibin of following mass fraction meter, 11 14 parts of Coixol, 16 20 parts of gemcitabine hydrochloride；Adult's dosage is 0.54mg active components/kg/ days.Western medicine compound of the present invention has functions that nourishing kidney-YIN, reduces blood sugar, and clinical test results show, the Western medicine compound has the advantages that reliable, safety evident in efficacy has no adverse reaction and toxic and side effect, it is adaptable to the clinical treatment of diabetes.
Description
Technical field
The present invention relates to Western medicine field, specifically a kind of Western medicine compound for treating diabetes and application.
Background technology
Diabetes are one group of metabolic diseases being characterized with hyperglycaemia.Hyperglycaemia be then due to defect of insulin secretion or
Its biological agent is damaged, or both have concurrently and cause.Long-standing hyperglycaemia during diabetes, cause various tissues, particularly eye,
Kidney, heart, blood vessel, chronic lesion, the dysfunction of nerve.
Diabetes are also called diabete, and the traditional Chinese medical science thinks that its origin cause of formation is more due to overfeeding delicious food, eating and drinking without temperance, inadequate natural endowment, element
Body yin deficiency, or give up completely to natural impulse, disorder of emotion, or internal lesion caused by overexertion excessively cause yin jin loss, scorching, more damage yin jin, the two each other because
Really.With blood as body, with gas as use, liver controlling conveyance and dispersion adjusts human physiological functions to liver, and irritability catharsis is then happy, and qi and blood is put down
With strongly fragrant and change fire if depressed emotion or rage impairing liver, then liquid is hindered in Tianjin of burning, and viscera function is disorderly, so as to cause diabetes.
At present, that prevents and treats diabetes it is critical only that holding blood sugar steadily and the control to its complication.Control the side of blood sugar
Method is not simple treatment, is less simple drug therapy, but proposes control diabetes according to the World Health Organization (WHO)
Five-term measure, i.e. diet control, kinesiatrics, drug therapy, diabetes education, blood sugar monitoring carry out integrated control.Wherein, medicine
Thing treatment is the key for controlling blood sugar.Although chemical sugar-lowering medicine can control hyperglycaemia to a certain extent, due to the poison of itself
The organs such as side effect, liver, kidney, the heart, brain to human body cause serious infringement, aggravate the development of complication.
The content of the invention
It is an object of the invention to provide a kind of evident in efficacy, Western medicine compound for the treatment of diabetes for having no toxic side effect and
Using.
To achieve the above object, the present invention provides following technical scheme：
A kind of Western medicine compound for treating diabetes, the active component of described Western medicine compound is by following mass fraction meter
1.2-1.7 parts of Korea's silibin, Coixol 11-14 parts, gemcitabine hydrochloride 16-20 parts composition.
As further scheme of the invention：The active component of described Western medicine compound by following mass fraction meter court
Fresh silibin 1.4-1.6 parts, Coixol 12-13 parts, gemcitabine hydrochloride 17-19 parts of composition.
As further scheme of the invention：The active component of described Western medicine compound by following mass fraction meter court
1.4 parts of fresh silibin, 13 parts of Coixol, 18 parts of compositions of gemcitabine hydrochloride.
As further scheme of the invention：Adult's dosage of described Western medicine compound is 0.5-0.6mg activity
Composition/kg/ days.
As further scheme of the invention：Adult's dosage of described Western medicine compound be 0.54mg activity into
Point/kg/ days.
The property of medicine of Western medicine is as follows used by Western medicine compound of the present invention：
Korea's silibin：For treat cholecystitis, cholangitis, cholelithiasis, bile duct partial blockage, acute, chronic hepatitis, courage high consolidate
Alcoholemia and liver originality edema.
Coixol：With effect that is antipyretic, easing pain and reduce blood pressure.
Gemcitabine hydrochloride：Suitable for treat inoperable late period or metastatic cancer of pancreas and treatment Local advancement or
Metastatic Nsclc, treatment Advanced non-small cell lung cancer, cancer of pancreas, carcinoma of urinary bladder, breast cancer and other entities are swollen
Knurl.
Application of the described Western medicine compound in treatment diabetes medicament is prepared.
Compared with prior art, the beneficial effects of the invention are as follows：Western medicine compound of the present invention has nourishing kidney-YIN, reduces blood
Sugared effect, clinical test results show that there is the Western medicine compound reliable, safety evident in efficacy to have no adverse reaction and the secondary work of poison
Advantage, it is adaptable to the clinical treatment of diabetes.
Specific embodiment
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described,
Obviously, described embodiment is only a part of embodiment of the invention, rather than whole embodiments.Based in the present invention
Embodiment, the every other embodiment that those of ordinary skill in the art are obtained under the premise of creative work is not made, all
Belong to the scope of protection of the invention.
Embodiment 1
In the embodiment of the present invention, a kind of Western medicine compound for treating diabetes, the active component of described Western medicine compound
It is made up of 1.2 parts of Korea's silibin of following mass fraction meter, 14 parts of Coixol, 16 parts of gemcitabine hydrochloride.
Embodiment 2
In the embodiment of the present invention, a kind of Western medicine compound for treating diabetes, the active component of described Western medicine compound
It is made up of 1.7 parts of Korea's silibin of following mass fraction meter, 11 parts of Coixol, 20 parts of gemcitabine hydrochloride.
Embodiment 3
In the embodiment of the present invention, a kind of Western medicine compound for treating diabetes, the active component of described Western medicine compound
It is made up of 1.4 parts of Korea's silibin of following mass fraction meter, 13 parts of Coixol, 17 parts of gemcitabine hydrochloride.
Embodiment 4
In the embodiment of the present invention, a kind of Western medicine compound for treating diabetes, the active component of described Western medicine compound
It is made up of 1.6 parts of Korea's silibin of following mass fraction meter, 12 parts of Coixol, 19 parts of gemcitabine hydrochloride.
Embodiment 5
In the embodiment of the present invention, a kind of Western medicine compound for treating diabetes, the active component of described Western medicine compound
It is made up of 1.4 parts of Korea's silibin of following mass fraction meter, 13 parts of Coixol, 18 parts of gemcitabine hydrochloride.
In above-described embodiment, the preparation process of the Western medicine compound of described treatment diabetes is：With Korea's silibin, Job's tears
Element and gemcitabine hydrochloride are active component, and using acceptable technique and auxiliary material in pharmacy, being made can in various pharmacies
The peroral dosage form of receiving.
Western medicine compound of the present invention has functions that nourishing kidney-YIN, reduces blood sugar.
Drug toxicology is tested
1st, acute toxicity test
It is experiment with peroral dosage form obtained in the embodiment of the present invention 5, using gastric infusion mode, successive administration 3 in 24h
It is secondary, per minor tick 4h, 18mg active components are administered every time, accumulation medicine total amount reaches 54mg active components/kg, clinical equivalent to people
100 times of consumption.After administration in 7d, mouse activity, feed, excretion are normal, well-grown, hair color light, its average weight
Increase with the extension of experimental period.Every mouse of post mortem at 8d, visually observes the heart, liver, spleen, lung, kidney, brain, chest
Gland, stomach, intestines etc. do not find color and paramophia, fail to measure median lethal dose (LD50).Result shows：Western medicine of the present invention
Composition is without acute toxic reaction.
2nd, long term toxicity test
It is experiment with peroral dosage form obtained in the embodiment of the present invention 5, using gastric infusion mode, by Western medicine of the present invention combination
Thing is divided into low dosage, middle dosage, three groups of high dose, the drug dose of each group is respectively 6.75,13.5,27mg active components/kg/
D, 12.5,25,50 times equivalent to clinical dosage.After gastric infusion 12 weeks, general shape of the Western medicine compound of the present invention to animal
Condition, hematological indices, blood parameters are without obvious influence, Systematic anatomy, organ coefficient and histopathological examination
No abnormal pathological change.It is discontinued 2 weeks and also has no substantially change.Result shows：Western medicine compound of the present invention is in long term toxicity
In experiment, overt toxicity reaction and delayed toxicity reaction are not found.It can be seen that, Western medicine compound non-toxic reaction of the present invention, for a long time
Drug safety reliability.
Pharmacodynamics test
1st, animal model
300 Wistar rats are chosen, body weight 180-220g, male and female half and half, rat is normally fed 1 week, first feeds with hyperpyrexia
Amount feed (lard 10%, sucrose 15%, yolk powder 15%, casein 5%, cholesterol 1.2%, sodium taurocholate 0.2%, bicarbonate
52.6%) calcium 0.6%, stone flour 0.4%, mouse maintain material, and after 4 weeks, fasting 12h, tail vein surveys fasting blood-glucose, weighs.Abdominal cavity
The streptozotocin 60mg/kg of injection 1%, it is the citric acid-sodium citrate that 4.2, concentration is 0.1mol/L that streptozotocin is dissolved in pH
In buffer solution, each dose is finished in 10min.The isometric citric acid-sodium citrate buffering of blank group rats by intraperitoneal injection
Liquid is normal to raise.Docking takes blood and surveys whole blood sugar after 10 days, is modeling success with the horizontal ＞ 10.0mmol/L persons of blood glucose value, with blood
The horizontal ＞ 15.0mmol/L persons of sugar value are stable type.
2nd, it is grouped and is administered
Stable type modeling success rat is randomly divided into model control group, Pioglitazone group, low dosage according to blood sugar level
Totally 5 groups, every group 10 of group, middle dose group, high dose group.Each group gives following medicines respectively：
Model control group：Gavage gives isometric physiological saline；
Pioglitazone group：Gavage gives Pioglitazone 3mg/kg/d；
Low dose group：Gavage gives Western medicine compound/kg/d obtained in 3.4mg embodiments 5；
Middle dose group：Gavage gives Western medicine compound/kg/d obtained in 6.8mg embodiments 5；
High dose group：Gavage gives Western medicine compound/kg/d obtained in 13.6mg embodiments 5.
Above-mentioned administration group is administered once a day, continuous 10 weeks.Blood sugar, urine are micro after blood sugar, administration before measure of taking a blood sample administration
Albumen and glycosylated hemoglobin.
3rd, assay method
1) measure of blood sugar：
After by stable type modeling success rat at random packet, according to dosage gastric infusion, continuous 10 weeks, normal to raise.It is all
Rat is respectively at 4 weeks interior tail veins that take weekly detect fasting blood-glucose (FBG) before administration and after administration.The blood sample of taking-up is put into
In protein precipitant, after room temperature places 7min, 5min is centrifuged under 3000r/min rotating speeds, takes supernatant, use glucose oxidase method
Survey whole blood sugar.
2) measure of microalbumin in urinating：
Reagent：PH is the glacial acetic acid solution that 2.8, volumetric concentration is 10%, and pH is that 3.0, molar concentration is 0.303mol/L
Glycine-glacial acetic acid buffer solution, molar concentration is the bromophenol blue storage liquid of 1.924mmol/L, and molar concentration is
The bromophenol blue developer of 0.231mmol/L.
The collection and detection of sample：Raised during rat is put in into metabolic cage respectively in the 1st, 3,5,7 and 10 weeks, collected overnight
Urinate within 12 hours, accurate recording urine volume.4ml is taken, after Sodium azide treatment, 10min is centrifuged under the rotating speed of 2000r/min, take supernatant
Put -20 DEG C of Refrigerator store urinary albumins to be measured.The albumin standards 400 for taking respective concentration is aobvious in corresponding cup, respectively Jia 200
Toner, mixes, with ultraviolet specrophotometer, in mensuration absorbance A under 600nm.
3) measure of glycosylated hemoglobin：
After by stable type modeling success rat at random packet, according to dosage gastric infusion, continuous 10 weeks, normal to raise.Last
Fasting 12h after administration, etherization, eye socket takes blood, and glycosylated hemoglobin is determined by specification in kit.
4th, result
The blood sugar of each group rat of table 1, microdose urine protein, glycosylated hemoglobin value (N=10)
Remarks：Compare with Pioglitazone group,#P ＜ 0.05, compare with Pioglitazone group, ##P ＜ 0.01；With model comparison
Group compares,*P ＜ 0.05, compare with model control group, * * P ＜ 0.01.
The blood sugar of each group rat, microdose urine protein, glycosylated hemoglobin result are as shown in table 1.
As can be seen from Table 1：In terms of to blood glucose in diabetic rats, microdose urine protein, the influence of glycosylated hemoglobin,
Pioglitazone group and Western medicine compound each group of the present invention compare with model control group significant difference, Western medicine combination of the present invention
Thing each group compares with model control group pole significant difference；Compared with Pioglitazone group, Western medicine compound each group of the present invention is in drop
Hypoglycemia aspect has pole significant difference, but curative effect does not have positive correlation with dosage；Compared with model control group, pyrrole lattice row
Glycosylated hemoglobin no difference of science of statistics after the administration of ketone group, the saccharification hemoglobin content of Western medicine compound each group of the present invention is equal
There is significant difference, wherein middle dose group has pole significant difference；The urine micro protein content of high dose group and middle dose group
With significant difference.
Clinical test
1st, basic data
The patient 400 that selection is diagnosed as diabetes carries out clinical observation, wherein, male 243, women 157, age
48-69 Sui, average age 61 years old, course of disease 1-7, average course of disease 3 years.400 patients are randomly divided into treatment 1-5 groups, control
Totally eight groups of 1-3 groups, every group 50, age of each group, sex, the course of disease, body weight, fasting blood-glucose (FBG) and 2 hours blood after breakfast
Sugar, is not statistically significant.
2nd, treatment method
Treatment 1-5 groups：Western medicine compound obtained in embodiment of the present invention 1-5 is taken respectively, twice daily, early, evening each one
It is secondary, the dosage equivalent to 16.2mg active components is each taken, before the meal warm water delivery service；20 days is 1 course for the treatment of, continuously treats 2-
3 courses for the treatment of, avoid during treatment：The food such as raw, cold, pungent, peppery, greasy.
Compare 1 group：Metformin hydrochloride tablet 0.5g is taken, it is oral that 2 times a day, and 1 tablet once, 2 groups is 1 treatment with 4 weeks
Journey, treats 3 courses for the treatment of altogether.
Compare 2 groups：The Western medicine compound taken only contains Coixol and gemcitabine hydrochloride, and remaining is complete with embodiment 5
It is identical.Twice daily, early, evening is each once, each takes the dosage equivalent to 16.2mg active components, before the meal warm water delivery service；
It is within 20 days 1 course for the treatment of, continuously the 2-3 course for the treatment of of treatment, avoids during treatment：The food such as raw, cold, pungent, peppery, greasy.
Compare 3 groups：The Western medicine compound taken only contains Korea's silibin, and remaining is identical with embodiment 5.Daily two
Secondary, early, evening is each once, each takes the dosage equivalent to 16.2mg active components, before the meal warm water delivery service；It is within 20 days 1 treatment
Journey, continuously the 2-3 course for the treatment of of treatment, avoids during treatment：The food such as raw, cold, pungent, peppery, greasy.
All patients keeping on a diet, move and diabetes education on the basis of, carry out medication treatment.
3rd, curative effect determinate standard
(1) it is effective：Symptom integral reduces that >=70%, FBG is normal or to decline more than 40%, HbAlc normal or decline 30%
More than, the improvement of TC, TG, LDL-C is more than 30% or recovers normal；
(2) effectively：Symptom integral reduces that >=30%, FBG is normal or to decline more than 20%, HbAlc normal or decline 10%
More than, TC, TG, LDL-C make moderate progress before relatively treating, but not enough effective standard；
(3) it is invalid：Clinical symptoms thing change aggravate or less than 30%, lab index it is unchanged or raise.
4th, treatment results
The comparitive study of each group of table 2
| Group | Case load | Effective number | Significant figure | Invalid number | Total effective rate |
| Treat 1 group | 50 | 22 | 21 | 7 | 86% |
| Treat 2 groups | 50 | 22 | 22 | 6 | 88% |
| Treat 3 groups | 50 | 23 | 21 | 6 | 88% |
| Treat 4 groups | 50 | 23 | 21 | 6 | 88% |
| Treat 5 groups | 50 | 25 | 21 | 4 | 92% |
| Compare 1 group | 50 | 20 | 20 | 10 | 80% |
| Compare 2 groups | 50 | 5 | 8 | 37 | 26% |
| Compare 3 groups | 50 | 0 | 6 | 44 | 12% |
By the 2-3 treatment of the course for the treatment of, the curative effect of each group is as shown in table 2.As can be seen from Table 2：Treatment group it is total effectively
Rate is 84-90%, and the therapeutic effect of Western medicine compound of the present invention is significantly better than control group, statistically significant (the P ＜ of difference
0.05)；By 5 groups of comparison therapy and control 2-3 groups, it is found that Korea's silibin has in Western medicine compound of the present invention irreplaceable
, important effect, Korea's silibin has obvious synergistic function with remaining component in Western medicine compound of the present invention.And whole
In individual therapeutic process, there is no obvious adverse reaction in each group.Therefore, Western medicine compound of the present invention is applied to controlling for diabetes
Treat.
5th, model case
Case 1：China certain, man, 67 years old, through hospital diagnosis be diabetes, limb edema, amblyopia, with diseases such as Nausea and vomitings
Shape, long term injections insulin takes 3 courses for the treatment of of Western medicine compound obtained in the embodiment of the present invention 5, and swelling disappears, vision restoration,
Nausea and vomiting symptom disappears, and blood sugar level recovers normal, and on inspection, the testing result of the glucose in serum of patient is
The testing result of 4.34mmol/L, C- peptide is 2.18ng/ml, the testing result of insulin is 12.78 μ IU/ml, the vein of patient
Glycosylated hemoglobin is 5.64% in anticoagulation, and in reference range, patient's above-mentioned testing result has fully recovered, follow-up 2 years,
The state of an illness is without repeatedly.
Case 2：Scape, female 59 years old, diabetes is obtained through hospital diagnosis, feels leg edema, eye-blurred, gluttonous, mouth
Yearningly, tooth is powerless, takes 2 courses for the treatment of of Western medicine compound obtained in the embodiment of the present invention 5, and edema disappears, and eyesight has been recovered, through inspection
Look into, the testing result of the glucose in serum of patient is 2.12ng/ml, insulin for the testing result of 4.65mmol/L, C- peptide
Testing result be 20.81 μ IU/ml, in the vein anticoagulation of patient glycosylated hemoglobin be 5.82%, above-mentioned testing result is equal
In reference range, patient has fully recovered, follow-up 2 years, and the state of an illness is without repeatedly.
Case 3：It is blue certain, female, 48 years old, be diabetes through hospital diagnosis, and eye-blurred is always wanted to eat, drunk water always, powerless body
There is necrosis in void, trick, and exanthemv, long term injections insulin takes Western medicine compound 2 obtained in the embodiment of the present invention 5
The course for the treatment of, glycemic control is steady, coordinates rational diet, has been extricated from the dependence to insulin injection, on inspection, the serum of patient
The testing result of middle glucose is for 1.86ng/ml, the testing result of insulin for the testing result of 5.31mmol/L, C- peptide
16.54 μ IU/ml, glycosylated hemoglobin is 6.36% in the vein anticoagulation of patient, and above-mentioned testing result is in reference range
Interior, patient has taken a turn for the better.
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, Er Qie
In the case of without departing substantially from spirit or essential attributes of the invention, the present invention can be in other specific forms realized.Therefore, no matter
From the point of view of which point, embodiment all should be regarded as exemplary, and be nonrestrictive, the scope of the present invention is by appended power
Profit requires to be limited rather than described above, it is intended that all in the implication and scope of the equivalency of claim by falling
Change is included in the present invention.
Moreover, it will be appreciated that although the present specification is described in terms of embodiments, not each implementation method is only wrapped
Containing an independent technical scheme, this narrating mode of specification is only that for clarity, those skilled in the art should
Specification an as entirety, the technical scheme in each embodiment can also be formed into those skilled in the art through appropriately combined
May be appreciated other embodiment.
Claims (6)
1. a kind of Western medicine compound for treating diabetes, it is characterised in that the active component of described Western medicine compound is by following
1.2-1.7 parts of Korea's silibin of mass fraction meter, Coixol 11-14 parts, gemcitabine hydrochloride 16-20 parts of composition.
2. it is according to claim 1 treatment diabetes Western medicine compound, it is characterised in that described Western medicine compound
Active component by following mass fraction meter 1.4-1.6 parts, Coixol 12-13 parts, gemcitabine hydrochloride 17-19 parts of Korea's silibin
Composition.
3. it is according to claim 2 treatment diabetes Western medicine compound, it is characterised in that described Western medicine compound
Active component is made up of 1.4 parts of Korea's silibin of following mass fraction meter, 13 parts of Coixol, 18 parts of gemcitabine hydrochloride.
4. according to the Western medicine compound of any described treatment diabetes of claim 1-3, it is characterised in that described Western medicine group
Adult's dosage of compound is 0.5-0.6mg active components/kg/ days.
5. it is according to claim 4 treatment diabetes Western medicine compound, it is characterised in that described Western medicine compound
Adult's dosage is 0.54mg active components/kg/ days.
6. the application according to any described Western medicine compounds of claim 1-3 in treatment diabetes medicament is prepared.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611227528.8A CN106727657A (en) | 2016-12-27 | 2016-12-27 | A kind of Western medicine compound for treating diabetes and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611227528.8A CN106727657A (en) | 2016-12-27 | 2016-12-27 | A kind of Western medicine compound for treating diabetes and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106727657A true CN106727657A (en) | 2017-05-31 |
Family
ID=58922201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611227528.8A Withdrawn CN106727657A (en) | 2016-12-27 | 2016-12-27 | A kind of Western medicine compound for treating diabetes and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106727657A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1703223A (en) * | 2002-10-09 | 2005-11-30 | 阿斯利康(瑞典)有限公司 | Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
| CN101040851A (en) * | 2006-03-20 | 2007-09-26 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | The use of dicaffeoylguinic acid ramification and the analog in the treatment of diabetes and the corresponding disease |
| CN102503907A (en) * | 2011-10-14 | 2012-06-20 | 辽宁仙鹤矿泉水有限公司 | Method for extracting coixol from rhizoma phragmitis |
-
2016
- 2016-12-27 CN CN201611227528.8A patent/CN106727657A/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1703223A (en) * | 2002-10-09 | 2005-11-30 | 阿斯利康(瑞典)有限公司 | Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
| CN101040851A (en) * | 2006-03-20 | 2007-09-26 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | The use of dicaffeoylguinic acid ramification and the analog in the treatment of diabetes and the corresponding disease |
| CN102503907A (en) * | 2011-10-14 | 2012-06-20 | 辽宁仙鹤矿泉水有限公司 | Method for extracting coixol from rhizoma phragmitis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI406666B (en) | Niu Zhangzhi for the treatment of diseases | |
| CN103784727A (en) | Traditional Chinese medicinal composition, compound preparation and application thereof | |
| Zubioli et al. | Pharmaceutical consultation as a tool to improve health outcomes for patients with type 2 diabetes | |
| Ali | Diabetes and you: A comprehensive, holistic approach | |
| CN109498731A (en) | A kind of tonifying speen and tonifying kidney tune sugar-pill and preparation method thereof for treating diabetes B Pishenqixu syndrome | |
| CN106727657A (en) | A kind of Western medicine compound for treating diabetes and application | |
| CN101264203B (en) | Chinese and western medicine composition for treating diabetes | |
| CN103181945B (en) | The purposes of Semen Luffae | |
| CN105250339A (en) | Composition capable of decreasing blood sugar and preparation method thereof | |
| CN101406642A (en) | Antihypelipidemic compound formulation | |
| CN105535195A (en) | Traditional Chinese medicine preparation for treating diabetes and preparation method and application thereof | |
| Alromaihi et al. | Challenges of type 2 diabetes in patients with alcohol dependence | |
| Baby et al. | Prescribing pattern of antidiabetic drugs for type 2 diabetic in tertiary care teaching hospital | |
| CN109223766A (en) | Improve the composition and preparation process that microcirculation in human body improves the immunity of the human body | |
| CN103272079B (en) | A kind of drug compound and application thereof for the treatment of diabetic nephropathy | |
| Ismaili et al. | Nursing Care in Children with Type 1 Diabetes Mellitus | |
| Floss et al. | Intravenous fluid therapy—background and principles | |
| CN100363000C (en) | Chinese and western medicines composition contg. Avandia and its prepn. method | |
| Thommasen et al. | Effect of devil's club tea on blood glucose levels in diabetes mellitus | |
| CN106466325A (en) | The medicine of a kind of prevention or treatment diabetes, compositionss and its preparation | |
| CN104083673A (en) | Traditional Chinese medicine composition for treating chronic glomerulonephritis and application of traditional Chinese medicine composition | |
| KMandal et al. | Diabetes: a pragmatic therapy with a goal to prevent end stage kidney disease and dialysis | |
| CN100381150C (en) | Composition comprising epalrestat | |
| Moller | Glucose control, cardiorespiratory fitness, and dietary composition in healthy men. | |
| CN115669935A (en) | Preparation for nourishing pancreas islet, reducing blood sugar, regulating blood pressure and blood fat and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170531 |
|
| WW01 | Invention patent application withdrawn after publication |